Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05471687
Other study ID # 69HCL19_0931
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 1, 2022
Est. completion date March 1, 2025

Study information

Verified date July 2022
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The optimal screening methods for coronary insufficiency, a frequent and pejorative complication in diabetics, are subject to debate, particularly in situations of silent myocardial ischemia. The contemporary strategy consists of pre-selecting asymptomatic patients at very high cardiovascular (CV) risk by performing a coronary calcium score. If this is found to be high >300 AU (Agatston units), the patient is suspected of being at high risk of silent myocardial ischemia (SMI), and the assessment is completed to exclude the presence of coronary artery disease likely to benefit from revascularization. The complementary evaluation consists in evaluating the myocardial perfusion to judge the perfusion repercussions. The most common examination to date is myocardial scintigraphy, because stress tests are too frequently submaximal in diabetics. However, the reproducibility of scintigraphy is controversial and their sensitivity and specificity are debated in this indication. This problem is similar in stable symptomatic coronary diabetic patients for whom an indication for functional examinations is justified. The double-energy double-layer spectral scanner (SDEDC) could now become a relevant tool in this field, since it can combine not only anatomical data (identification of coronary stenosis) but also functional data (myocardial perfusion) during a stress protocol. thanks to the spectral images which make it possible to measure the tissue concentration of intramyocardial iodine downstream of the considered stenosis.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 150
Est. completion date March 1, 2025
Est. primary completion date September 1, 2024
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - Aged man =50 years old or woman aged =55 years old, (age difference justified for established menopause which increases the CV risk and to avoid the risk of CT scan during pregnancy) - Diabetic (type 1 or type 2 or type 3): - Asymptomatic, falling within the scope of screening for silent myocardial ischemia and having a CAC > 300 AU or - Symptomatic on the coronary level, within the framework of the evaluation of symptomatic coronary insufficiency with positive myocardial scintigraphy. - Patient having agreed to participate in the study and signed a written informed consent - Patient affiliated to a social security scheme or similar Exclusion Criteria: Drug intolerance (adenosine, and/or contrast product used (Iomeron)) Related to iodine injection: - History of major immediate or delayed skin reaction + hypersensitivity to the active substance or to any of the excipients - Renal failure with GFR < 45 ml/min - - Known autonomic goiter with risk of thyrotoxicosis - No suspension of the biguanide the same day of the examination (and resumed 48 hours later) Linked to the injection of adenosine and regadenoson (Cf SPC Adenoscan combination with dipyridamole) - 2nd or 3rd degree BAV not fitted, sinus dysfunction not fitted, - Long QT syndrome, - Decompensated heart failure, - Unstable angina / Acute coronary syndrome / ATCD IDM less than a year old - BP > 1800 mmHg < 100 mmHg - Known stenosis of the common trunk (left), - Tight heart valve stenosis. - Uncorrected hypovolemia, - Chronic obstructive pulmonary disease with clinical bronchospasm (e.g. bronchial asthma) - Comitiality - No suspension of dipyridamole (during the 48 hours before the examination) - Severe hypotension - Consumption of coffee, tobacco, tea, cola, banana, chocolate consumed before the examination (usual instructions in the event of myocardial stress protocol by adenosine agonist during the scintigraphy) - Contraindication to adenosine: severe hypotension Related to scanner performance - patient unable to maintain apnea. - Calcium score > 500 on the common trunk - Temporary suspension of bradycardia or anti-anginal on the day of the examination (beta blocker, calcium channel blocker) not carried out. Related to the patient's context - Person unable to express their consent. - Patient under guardianship, curatorship or safeguard of justice

Study Design


Related Conditions & MeSH terms


Intervention

Device:
dual-energy dual-layer spectral scanner
Realization of dual-energy dual-layer spectral scanner with stress protocol
Drug:
Stress protocol with adenosin during dual-energy dual-layer spectral scanner
Injection of intraveinous adenosin dose 0.78 mg/kg during dual-energy dual-layer spectral scanner

Locations

Country Name City State
France Hospices Civils de Lyon Bron

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Identification of tight coronary stenoses justifying coronary angiography An anomaly considered significant corresponds to:
the presence of coronary stenosis >50% with significant hypoperfusion or stenosis > 75% by spectral CT (SDEDC)
of a significant hypoperfusion on myocardial scintigraphy (SPECT)
Reading Committee: Creation of a blind review committee for myocardial SPECT scans and the SDEDC spectral scanner, without knowledge of the coronary angiography data or the other perfusion examination for statistical comparison.
Measured at day 0
Secondary Identification of tight coronary stenoses justifying a coronary angiography including a measurement of the Fractional Flow Reserve (FFR) An anomaly considered significant corresponds to:
the presence of coronary stenosis >50% with significant hypoperfusion or stenosis > 75% by spectral CT (SDEDC)
of a significant hypoperfusion on myocardial scintigraphy (SPECT)
Reading Committee: Creation of a blind review committee for myocardial SPECT scans and the SDEDC spectral scanner, without knowledge of the coronary angiography data or the other perfusion examination for statistical comparison.
Measured at day 0
Secondary Sensitivity and specificity of the study Sensitivity and specificity of the study of the perfusion at rest during the SDEDC: 1 to 1 comparison of the data of the SDEC at rest (stenosis and perfusion) with the FFR; with the sensitivities and specificities of SDEDC perfusion to stress; with SPECT scintigraphy under stress.
Reading Committee: Creation of a blind review committee for myocardial SPECT scans and the SDEDC spectral scanner, without knowledge of the coronary angiography data or the other perfusion examination for statistical comparison.
Measured at day 0
Secondary Proportion of mismatches in diabetics and their predisposing factors Proportion of mismatches in diabetics and their predisposing factors by identifying tissue perfusion defects (SPECT or SDEDC positive) in patients with a coronary network without angiographically tight stenosis (negative coronarography).
Reading Committee: Creation of a blind review committee for myocardial SPECT scans and the SDEDC spectral scanner, without knowledge of the coronary angiography data or the other perfusion examination for statistical comparison.
Measured at day 0
Secondary Collection of the subjective assessment of the 2 examinations (SDEDC and myocardial scintigraphy) Collection of the subjective assessment of the 2 examinations (SDEDC and myocardial scintigraphy) by the patients using a satisfaction questionnaire by telephone call. Measured at day 1 and 2
See also
  Status Clinical Trial Phase
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT03427996 - Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice
Terminated NCT03175523 - HOW To Optimally Implant BioResorbable Scaffold - Intravascular Imaging Versus Quantitative Coronary Angiography Guidance N/A
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Completed NCT01184183 - Trial Comparison of Accuseal and Bovine Pericardial Patch During Endarterectomy
Completed NCT00697372 - SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis Phase 4
Completed NCT05509296 - Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease N/A
Recruiting NCT03054324 - Validation of a Predictive Model of Coronary Fractional Flow Reserve in Patients With Intermediate Coronary Stenosis
Enrolling by invitation NCT06194526 - Whole Blood Transcriptomic Signal According to Coronary Atherosclerotic Plaque Burden Assessed by CT Angiography
Not yet recruiting NCT06039748 - Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study
Not yet recruiting NCT05753085 - Multimodality Optical and Ultrasound Intravascular Imaging for Stent Optimization and Atheroma Assessment N/A
Not yet recruiting NCT04569669 - The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis N/A
Active, not recruiting NCT02508714 - Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents N/A
Completed NCT03301246 - Artimes Pro Low Profile Dilatation Catheters for Pre-Dilatation in Patients With Symptomatic Ischemic Heart Disease N/A
Completed NCT03606330 - Systemic, Pancoronary and Local Coronary Vulnerability
Completed NCT02870140 - Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent N/A
Not yet recruiting NCT06071702 - IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System N/A
Completed NCT02275143 - Computed Tomography (CT) Coronary Angiogram Evaluation in Cancer Patients Having CT Thorax, Abdomen and Pelvis N/A
Active, not recruiting NCT01794065 - The Promus Element Rewards Study N/A
Completed NCT02120859 - Optical Coherence Tomography to Investigate FFR-Guided DEB-only Elective Coronary Angioplasty Phase 4